Search

everythinglearnresearchcommunity

for

Search:↓

A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

Baldness is often preventable with treatments like dutasteride, oral minoxidil, or finasteride. Many people fail to address it due to misinformation or lack of commitment.

The conversation is about dealing with hair loss during university, with the original poster using dutasteride and minoxidil as treatments. Participants share their experiences and coping strategies, such as wearing hats, considering going completely bald, or getting a hair transplant after graduation.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

After years of using dutasteride and oral minoxidil without success, the individual decided to shave their head and stop treatment. They considered scalp micropigmentation and hair systems but ultimately accepted their hair loss.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

Hair loss discussion involving finasteride's side effects and effectiveness. Users shared mixed experiences, with some reporting side effects and others seeing positive results.

A user is trying to reverse male pattern baldness (MPB) naturally by taking high doses of Vitamin D, improving diet, exercising, reducing stress, and other lifestyle changes, but plans to use finasteride if no results are seen in 60 days. Other users are skeptical, advising medical treatments like finasteride and warning against potential vitamin D overdose and the ineffectiveness of natural remedies for genetic hair loss.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

A 20-year-old stopped oral minoxidil (3mg) for a month due to health concerns and lack of significant results, while continuing topical minoxidil (7%) with tretinoin and finasteride (1mg). They experienced placebo side effects and are considering resuming oral minoxidil, seeking advice on potential setbacks.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

Despite using finasteride, minoxidil, and RU58841, the user is experiencing slow hair loss, particularly at the hairline, and is considering additional treatments like microneedling and possibly switching to dutasteride. Concerns about medication side effects, such as reduced sperm count and performance anxiety, are also discussed.

The user is using finasteride and minoxidil for hair loss but feels progress is slow and is considering switching to dutasteride after 12 months. They notice minor shedding but are unsure if the medication is stabilizing their hair loss.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.

The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

The user has been on finasteride for over four years without noticeable results and recently added dutasteride and RU58841, but continues to experience hair loss. They are considering stopping all medications due to lack of effectiveness and side effects like extremely dry eyes from dutasteride.